209 related articles for article (PubMed ID: 6139329)
1. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.
Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM
Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
3. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
George SR; Hegele RA; Burrow GN
Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
[TBL] [Abstract][Full Text] [Related]
4. Differences between somatostatin-28 and somatostatin-14 with respect to their biological effects in healthy humans and acromegalics.
Hadjidakis DJ; Raptis SA; Souvatzoglou A; Karaiskos C; Diamantopoulos EJ; Moulopoulos SD
Clin Physiol Biochem; 1986; 4(6):372-83. PubMed ID: 2880690
[TBL] [Abstract][Full Text] [Related]
5. Development of specific and non-specific somatostatin analogs.
Nakano T; Harano Y; Emura J; Kimura T; Sakakibara S; Shigeta Y
Horm Metab Res; 1986 Feb; 18(2):98-102. PubMed ID: 2870971
[TBL] [Abstract][Full Text] [Related]
6. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
Neuhaus C; Kerner W; Maier V; Pfeiffer EF
Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
[TBL] [Abstract][Full Text] [Related]
7. Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo.
Lins PE; Efendić S; Meyers CA; Coy DH; Schally A; Luft R
Metabolism; 1980 Aug; 29(8):728-31. PubMed ID: 6105610
[TBL] [Abstract][Full Text] [Related]
8. Effect of the somatostatin analog D-Trp8,D-Cys14 on glucose insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics.
Trovati M; Massara F; Camanni F; Molinatti GM; Lorenzati R; Pagano GF
J Endocrinol Invest; 1980; 3(2):189-92. PubMed ID: 6104680
[TBL] [Abstract][Full Text] [Related]
9. [The effects of somatostatin in acromegaly].
Schaison G; Roger M; Milhaud G
Nouv Presse Med; 1976 Mar; 5(10):629-32. PubMed ID: 772591
[TBL] [Abstract][Full Text] [Related]
10. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
Hansen AP; Christensen SE; Lundbaek K
Scand J Clin Lab Invest; 1975 May; 35(3):205-10. PubMed ID: 1153917
[TBL] [Abstract][Full Text] [Related]
11. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
Gerich JE; Lorenzi M; Bier DM; Tsalikian E; Schneider V; Karam JH; Forsham PH
J Clin Invest; 1976 Apr; 57(4):875-84. PubMed ID: 820717
[TBL] [Abstract][Full Text] [Related]
12. [Effects of somatostatin of plasma levels of glucose, insulin and growth hormone in acromegaly].
Porzio G; Massara F; Camanni F; Rizzi G; Molinatti GM
Minerva Med; 1976 Oct; 67(50):3241-2. PubMed ID: 995281
[No Abstract] [Full Text] [Related]
13. Excessive glucagon responses to arginine in active acromegaly.
Goldfine ID; Kirsteins L; Lawrence AM
Horm Metab Res; 1972 Mar; 4(2):97-100. PubMed ID: 5063721
[No Abstract] [Full Text] [Related]
14. Somatostatin: a review of its effects especially in human beings.
Hansen AP; Lundbaek K
Diabete Metab; 1976 Dec; 2(4):203-18. PubMed ID: 190058
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic action of somatostatin after oral glucose loading: due to suppression of glucagon and growth hormone or of intestinal carbohydrate absorption?
Bratusch-Marrain P; Vierhapper H; Grubeck-Loebenstein B; Waldhäusl W; Nowotny P
Horm Metab Res; 1981 Jun; 13(6):305-9. PubMed ID: 6114914
[TBL] [Abstract][Full Text] [Related]
16. An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs.
Gordin A; Meyers C; Arimura A; Coy DH; Schally AV
Acta Endocrinol (Copenh); 1977 Dec; 86(4):833-41. PubMed ID: 335762
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
18. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
[TBL] [Abstract][Full Text] [Related]
19. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
Lien EL; Garsky VM
Horm Metab Res; 1981 Dec; 13(12):675-8. PubMed ID: 6119282
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly.
Dunn PJ; Donald RA; Espiner EA
Clin Endocrinol (Oxf); 1976 Mar; 5(2):167-74. PubMed ID: 1269163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
